$46.63
0.15% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
GB00BYMT0J19
Symbol
LIVN

Livanova PLC Stock price

$46.63
+1.40 3.10% 1M
-5.48 10.52% 6M
+0.32 0.69% YTD
-6.18 11.70% 1Y
-0.93 1.96% 5Y
-14.80 24.09% 10Y
+7.30 18.56% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
-0.07 0.15%
ISIN
GB00BYMT0J19
Symbol
LIVN
Sector

Key metrics

Market capitalization $2.54b
Enterprise Value $2.43b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 16.72
EV/Sales (TTM) EV/Sales 1.91
P/S ratio (TTM) P/S ratio 1.99
P/B ratio (TTM) P/B ratio 2.46
Revenue growth (TTM) Revenue growth 7.62%
Revenue (TTM) Revenue $1.28b
EBIT (operating result TTM) EBIT $179.58m
Free Cash Flow (TTM) Free Cash Flow $145.52m
Cash position $738.44m
EPS (TTM) EPS $-4.09
P/E forward negative
P/S forward 1.91
EV/Sales forward 1.83
Short interest 4.31%
Show more

Is Livanova PLC a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Livanova PLC Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Livanova PLC forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Livanova PLC forecast:

Buy
89%
Hold
11%

Financial data from Livanova PLC

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,275 1,275
8% 8%
100%
- Direct Costs 391 391
3% 3%
31%
884 884
10% 10%
69%
- Selling and Administrative Expenses 530 530
1% 1%
42%
- Research and Development Expense 175 175
8% 8%
14%
222 222
60% 60%
17%
- Depreciation and Amortization 42 42
13% 13%
3%
EBIT (Operating Income) EBIT 180 180
100% 100%
14%
Net Profit -222 -222
599% 599%
-17%

In millions USD.

Don't miss a Thing! We will send you all news about Livanova PLC directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Livanova PLC Stock News

Neutral
Business Wire
8 days ago
LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced completion of the CORE-VNS study further validating effectiveness of VNS Therapy for severe focal seizures in children & adults.
Neutral
Business Wire
8 days ago
LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced CORE-VNS 24-month data show adjunctive VNS Therapy associated with substantial reduction in generalized tonic-clonic seizures.
Neutral
Business Wire
9 days ago
LONDON--(BUSINESS WIRE)-- #depression--LivaNova PLC announced it initiated the process with U.S. CMS to seek reconsideration of national Medicare coverage for VNS Therapy in depression.
More Livanova PLC News

Company Profile

LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular and Neuromodulation. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and advanced circulatory support products. The Neuromodulation segment designs and markets NM-based medical devices for the treatment of epilepsy, depression, and obstructive sleep apnea. The company was founded on February 20, 2015 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Vladimir Makatsaria
Employees 2,900
Founded 1987
Website www.livanova.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today